论文部分内容阅读
目的:此次课题主要选取了到我院接受治疗晚期非小细胞肺癌患者,探讨了恩度联合化疗对患者治疗的有效性及安全性.方法:本课题研究主要的研究样本是选择来我院接受治疗的晚期非小细胞肺癌患者,样本量抽取80例,然后采用入院就诊先后顺序法将这些样本量分两组,其中一个组设定成常规组,该组中的晚期非小细胞肺癌患者共有40例,所有患者均采取常规化疗,另外一个组则设定为研究组,该组中的晚期非小细胞肺癌患者共有40例,所有患者在常规化疗的基础上恩度进行联合治疗;样本分组完成之后,对两组患者的临床治疗效果、不良反应发生情况、血管新“,”Objective this subject mainly selected patients who visited our hospital for the treatment of advanced non-small cell lung cancer,in order to explore the efficacy and safety of Endo combined with chemotherapy on patients\'\' treatment.Methods:the main research sample of this subject study was the selection of advanced NSCLC patients who came to our hospital for treatment,the sample size was 80 cases,and then these sample sizes were divided into two groups using the sequential method of admission visit followed by conventional chemotherapy,one group was set into the conventional group,the advanced NSCLC patients in this group had a total of 40 cases,and all patients were treated with conventional chemotherapy,An additional group was set up as the study group,which consisted of 40 patients with advanced NSCLC,all of whom were enroled on the basis of conventional chemotherapy;After completion of sample grouping,statistical evaluation of clinical treatment effects,occurrence of adverse effects,indicators of angiogenesis and immune function was performed in both groups.Results:in view of the data obtained during the experimental study,it was possible to master that after a period of treatment,analysis of the clinical treatment effect of the two groups of patients showed that the clinical treatment effect of the patients in the study group was significantly better than that of the conventional group(P ＜ 0.05);Analysis of the occurrence of adverse events in both groups revealed that the incidence of adverse events was significantly lower in the study group than in the conventional group(P ＜ 0.05;Analysis of the indicators of angiogenesis before and after treatment in both groups revealed that patients in the study group were significantly better than those in the conventional group for each indicator after treatmen(t P ＜ 0.05;Analysis of each immune function measure in both groups revealed that all immune function measures were significantly higher in the study group than in the conventional group(P ＜ 0.05).Conclusion:Patients with advanced NSCLC should be treated with lenalidomide chemotherapy,which can significantly improve the indicators of angiogenesis and each immune function and reduce the risk of adverse effects,while effectively improving the clinical outcomes of patients,The efficacy and safety profile of the combination chemotherapy regimen of Endostar is remarkable,but it will also be instructive for subsequent studies.